This page contains a Flash digital edition of a book.

outcomes. The development of prospective studies aimed at bringing these new tools together in the best treatment strategy for each individual patient should be the ultimate goal. l

References 1. Alegre A et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002;87:609–14.

2. Lenhoff S et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006;91: 1228–33.

3. López A VM et al. Phase III trial of bortezomib, melphalan, and prednisone (VMP) versus bortezomib, thalidomide, and prednisone (VTP) in elderly multiple myeloma (MM) patients: update follow-up, patterns management of first relapse/ progression. ASH 2013 Annual Meeting Abstract.

4. Mikhael JR. A practical approach to relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2014;2014:262–7.

5. Torimoto Y et al. Current therapeutic strategies for multiple myeloma. Int J Clin Oncol 2015;April.

6. Knopf KB et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2014;14:380–8.

7. Madan S et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011;118:1763–5.

8. Singhal S et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999,341:1565–71.

9. Pineda-Roman M et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008;22:1419–27.

10. Gerrie AS et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 2013;161:802–10.

11. Weber DM et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.

12. Dimopoulos M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.

13. Baz R et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766–71.


14. Knop S et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

Blood 2009;113:4137–43.

15. van de Donk NW et al. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010;148:335–7.

16. Morgan GJ et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268–9.

17. Richardson PG et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014;123: 1826–32.

18. Leleu X et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood 2015;125:1411–17.

19. Richardson PG et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–17.

20. Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431–40.

21. Scheid C et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014;99:148–54.

22. Neben K et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940–8.

23. Orlowski RZ et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–901.

24. Reeder CB et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115: 3416–17.

25. Richardson PG et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713–19.

26. Demo SD et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383–91.

27. Stewart AK et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–52.

28. Shah JJ, Abonour R. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory. 54th ASH Annual Meeting, Atlanta, GA, 2012:abstr 74. 29. Michaelis LC et al. Salvage second hematopoietic cell

transplantation in myeloma. Biol Blood Marrow Transplant 2013;19:760–6.

30. Chow AW et al. Relapsed multiple myeloma: who benefits from salvage autografts? Intern Med J 2013;43:156–61.

31. Doo NW et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 2013;54:1465–72.

32. Thompson PA et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011;46:764–5.

33. Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 2014;28:891–902.

34. Kumar SK et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149–57.

35. Ocio EM et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525–42.

36. San-Miguel JF et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195–206.

37. Lonial S et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953–9.

38. Zonder JA et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552–9.

39. Moreau P MM et al. An open-label, multicenter, phase 1b study of Daratumumab in combination with backbone regimens in patients with multiple myeloma. 56th ASH Annual Meeting, San Francisco, CA 2014:abstr 176.

40. Martin TG et al. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies data from a dose-escalation phase I study. 53rd ASH Annual Meeting, New Orleans, LA 2013:abstr 284.

41. Ludwig H et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28:981–92.

42. de la Rubia J, Roig M. Bortezomib for previously untreated multiple myeloma. Expert Rev Hematol 2011,4:381–98.

43. Bergsagel PL et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884–92.

44. van de Donk NW et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011,37:266–83.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32